ETERN Therapeutics

ETERN was established in 2018, focusing on the research and development of small molecule drugs targeting protein liquid-liquid phase separation. The LLPS platform, the state-of-art protein liquid-liquid phase separation platform developed by Etern, integrate cutting edge techniques including protein phase separation biology, AI-based target identification and verification, phase separation-based phenotypic screening, image recognition-based hit finding, etc. The platform provides a novel strategy for drug R&D, especially for “undruggable"targets.